CHO-K1 Stable Cell Line Generation

One of the key advantages of CHO cells is their ability to produce complex proteins that are human-compatible, with post-translational modifications, such as glycosylation. This feature increases therapeutic efficacy, protein longevity, and reduces safety concerns. Furthermore, CHO cells are highly stable, having a high tolerance for fluctuations in temperature, acidity (pH), oxygen, and cell density. This adaptability makes them suitable for large-scale manufacturing, and the product can be delivered in up to several grams per liter.²

Stable expression involves the integration of the gene of interest into the genome of the host cell line, allowing for long-term, heritable expression. This is typically achieved by using viral vectors or plasmids containing the gene of interest and a selectable marker (e.g., antibiotic resistance gene) to facilitate the selection and isolation of cells that have successfully integrated the gene.

Transient expression involves the direct introduction of the gene of interest into the host cells without integration into the genome. This is usually achieved through methods like transfection or electroporation.

The use of either depends on your research goals. Typically, for long-term studies or consistent gene expression across multiple experiments, stable expression is preferred. But for quick screening or short-term experiments, transient expression can be more suitable.

There is an increasing number of recombinant antibodies being developed as therapeutic agents, with about 40 new antibody molecules undergoing clinical trials every year, most of which are produced from CHO cells.^3,4 For instance, Trastuzumab is a therapeutic antibody that was expressed by CHO cells and is specific for the human epidermal growth factor receptor 2 (HER2).